No Data
No Data
Bristol Myers' Opdivo Fails in Phase 3 Lung Cancer Study
Bristol Myers (NYSE:BMY) said that a Phase 3 study of Opdivo with Yervoy with in the treatment of advanced lung cancer failed to meet its primary endpoint of progression-free survival.
Bristol-Myers Squibb Says Phase 3 Trial of Opdivo in Lung Cancer Fails to Meet Primary Endpoint
Bristol-Myers Squibb (BMY) said late Friday a phase 3 trial assessing Opdivo to potentially treat non-small cell lung cancer failed to reach its primary endpoint of progression-free survival. The tria
Bristol Myers Squibb Cancer-Treatment Trial Misses Endpoint
By Ben Glickman Bristol Myers Squibb said on Friday that its trial evaluating a combination of cancer treatments failed to meet its primary endpoint. The company's trial was evaluating the cancer-dr
Express News | Bristol Myers Squibb Shares Are Trading Lower After the Company's Phase 3 CheckMate -73L Trial Did Not Meet Its Primary Endpoint
Express News | Bristol-Myers Squibb Co: Opdivo and Opdivo-Based Combinations Have Shown Positive Outcomes
Express News | Bristol-Myers Squibb Co - Announced Phase 3 Checkmate -73L Trial Did Not Meet Its Primary Endpoint of Progression-Free Survival
No Data